Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Eli Lilly and Company (LLY) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly and Company (LLY) - $25 value - yours FREE >>
Image: Bigstock
Impel (IMPL) Gets FDA Nod for Trudhesa in Migraine Treatment
Impel NeuroPharma, Inc. announced that the FDA has approved its lead product, Trudhesa nasal spray (0.725 mg per spray), for the acute treatment of migraine in adult patients with or without aura. The product is expected to be launched early next month.
The new drug application for Trudhesa was based on data from the phase III STOP 301 study. The primary goal of the study was to assess the safety and tolerability of Trudhesa. Data form the same showed that treatment with Trudhesa was generally well tolerated, and exploratory efficacy findings showed that it provided rapid, sustained and consistent symptom relief.
Data from the study showed that treatment with Trudhesa led to consistent efficacy even when taken late into a migraine attack, unlike other oral acute treatments that need to be taken within one hour of the attack to be most effective. There was no serious treatment-emergent adverse event reported in the STOP 301 study.
Per the company, following the FDA nod, Trudhesa became the first and only therapeutic to use precision olfactory delivery technology to deliver dihydroergotamine mesylate to the vascular-rich upper nasal space.
Shares of Impel have rallied 76.3% in the past three months compared with the industry’s rise of 2.1%.
Image Source: Zacks Investment Research
We remind investors that Impel started trading on the NASDAQ stock exchange following its initial public offering on Apr 23, 2021.
Aprat from Trudhesa (previously known as INP104), Impel has other pipeline candidates that are also making good progress. The company is developing INP105 for the acute treatment of agitation in patients with autism and INP107 for treating OFF episodes in Parkinson’s disease.
We note that the migraine market is heavily crowded with several anti-CGRP drugs like Amgen’s (AMGN - Free Report) Aimovig, Lilly’s (LLY - Free Report) Emgality, Teva’s Ajovy and AbbVie’s (ABBV - Free Report) oral drug, Ubrelvy, already approved by the FDA for the given indication.
Zacks Rank
Impel currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.